Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 2, 2013, Pages 181-185

  Muluneh, B ^a   Dean, A ^a   Armistead, P ^b   Khan, T ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

acyclovir; bone marrow; cidofovir; hematopoietic stem cell transplant; HSV; Topical

Indexed keywords

ACICLOVIR; CIDOFOVIR; CYCLOPHOSPHAMIDE; DASATINIB; FOSCARNET; METHOTREXATE; PREDNISONE; STEROID; TACROLIMUS; VALACICLOVIR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BLAST CELL CRISIS; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COLONOSCOPY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; LUNG HEMORRHAGE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; REPEAT PROCEDURE; TREATMENT DURATION; ULCER; ULCER HEALING; VIRAL CLEARANCE; VIRUS RESISTANCE; WHOLE BODY RADIATION;

ACYCLOVIR; BONE MARROW; CIDOFOVIR; HEMATOPOIETIC STEM CELL TRANSPLANT; HSV; TOPICAL;

ACYCLOVIR; ADMINISTRATION, TOPICAL; ADULT; ANTIVIRAL AGENTS; CYTOSINE; DRUG RESISTANCE, VIRAL; FEMALE; FOSCARNET; GELS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; ORGANOPHOSPHONATES; REAL-TIME POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84875580167     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212448408     Document Type: Article

References (18)

1. Vistide [prescribing information]. Foster City, CA: Gilead Pharmaceuticals Corporation ; August 2011 :
2. McElhiney LF. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Comp. 2006 ; 10 (5). 324-328
3. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997 ; 176 (4). 892-898
4. Lateef F. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol. 1998 ; 134 (9). 1169-1170
5. Sims CR. Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. Transpl Infect Dis. 2007 ; 9 (3). 256-259
6. Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation. 2002 ; 73 (4). 661-662
7. Snoeck R, Wellens W, Desloovere C, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine]. J Med Virol. 1998 ; 54 (3). 219-225
8. Van Cutsem E, Snoeck R, Van Ranst M, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol. 1995 ; 45 (2). 230-235
9. Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med. 1995 ; 333 (14). 934-943
10. Douglas J, Corey T, Tyring S, et al. A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection.. Poster presented at: 4th Conference on Retroviruses and Opportunistic Infections ; 22-26 January 1997, poster #334 ;..
11. Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 1997 ; 133 (8). 987-990
12. Davies EG, Thrasher A, Lacey K, et al. Topical cidofovir for severe molluscum contagiosum. Lancet. 1999 ; 353 (9169). 2042-2042
13. Zabawski EJ, Cockerell CJ. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol. 1999 ; 16 (5). 414-415
14. Huggins JW, Smee D, Martinez M, et al. Cidofovir(HPMPC) treatment of monkeypox. Abstract presented at: 11th International Conference on Antviral Research ; 5 - 10 April 1998, abstract #118 ;..
15. Gilead announces phase I/II data insufficient for marketing clearance of FORVADE[tm] topical gel to treat refractory herpes in patients with AIDS. Press Release, Foster City, CA, 6 May 1997 ; May 6, 1997 :
16. Gliead sciences. Gilead files NDA for cidofovir gel - drug aimed at refractory genital herpes. Biotechnol Law Report. 1997 ; 16 (2). 181-182
17. Center for Disease Control. National Institute for Occupational Safety and Health (NIOSH) List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010. http://www.cdc.gov/niosh/docs/2010-167/pdfs/2010-167. pdf.
18. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011 ; 55 (2). 459-472